
Sign up to save your podcasts
Or


Our co-hosts discuss NRG-GU006 with Dr. Daniel Spratt. The results of NRG-GU006, a phase II clinical study in recurrent prostate cancer, were presented as a part of the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting Clinical Trials Session.
By NRG Oncology5
1010 ratings
Our co-hosts discuss NRG-GU006 with Dr. Daniel Spratt. The results of NRG-GU006, a phase II clinical study in recurrent prostate cancer, were presented as a part of the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting Clinical Trials Session.

228,737 Listeners

6,808 Listeners

30,666 Listeners

8,766 Listeners

522 Listeners

29,737 Listeners

2,438 Listeners

112,194 Listeners

9,517 Listeners

62 Listeners

9,926 Listeners

15,855 Listeners

2,227 Listeners

37 Listeners

5 Listeners